H2受容体拮抗薬の世界市場レポート 2025年

H2受容体拮抗薬市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.5％で53億5,000万米ドルに成長します。予測期間における成長の原動力は、生活習慣に関連した消化器疾患の症例の増加、非処方胃腸治療薬への需要の増加、慢性的な酸の問題を抱える老人人口の増加、ジェネリック製剤の利用可能性の拡大、小児にやさしい製剤の開発などです。予測期間中に予想される主な動向には、徐放性製剤の開発、デジタルヘルスモニタリングツールとの統合、小児用剤形の革新、プロバイオティクスとの併用療法、高温気候に対応した化合物の安定性の発展などがあります。

胃腸疾患の罹患率の増加がH2受容体拮抗薬市場の成長を牽引すると予想されます。消化管疾患とは、感染症、炎症、胃や腸の障害など、消化管に影響を及ぼす疾患のことです。胃腸疾患の増加は、不健康な食習慣や加工食品の消費の増加に大きく起因しており、これらは腸の健康を乱し、胃酸逆流、過敏性腸症候群（IBS）、潰瘍などの消化器疾患を引き起こす可能性があります。H2受容体拮抗薬は、胃のヒスタミン受容体をブロックし、酸の産生を抑え、酸逆流、潰瘍、胃炎などの症状を緩和することにより、これらの症状に対処します。例えば、2023年1月、米国がん協会（ACS）は、米国における消化器がんの症例数が3.18％増加し、2022年の338,090例から2023年には348,840例に増加すると報告しています。その結果、消化器疾患の罹患率の増加がH2受容体拮抗薬市場の拡大を牽引しています。

H2受容体拮抗薬市場の企業は、新規ドラッグデリバリーシステムなどの革新的ソリューションの開発に注力し、酸抑制治療の有効性、利便性、患者のコンプライアンスを向上させています。新規ドラッグデリバリーシステムは、治療薬を制御された標的で持続的に放出し、有効性を高め、患者の服薬アドヒアランスを向上させるように設計された先進技術です。例えば、2022年6月、インドの製薬会社ザイダス・ライフサイエンシズ社は、GERDなどの酸関連疾患治療用の口腔内崩壊錠であるファモチジンODTを発売しました。この製剤により、特に嚥下困難な患者でも水なしで服用できるようになり、利便性とコンプライアンスが向上しました。ザイダス社は、この技術革新により薬が使いやすくなり、より迅速な緩和が得られることで、より良い治療結果が得られると強調しています。このような送達システムの採用は、患者の治療体験とアクセシビリティを向上させることで、H2受容体拮抗薬市場の成長を後押ししています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界のH2受容体拮抗薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のH2受容体拮抗薬市場：成長率分析
• 世界のH2受容体拮抗薬市場の実績：規模と成長、2019年～2024年
• 世界のH2受容体拮抗薬市場の予測：規模と成長、2024年～2029年、2034年
• 世界のH2受容体拮抗薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のH2受容体拮抗薬市場：薬剤クラス別、実績と予測、2019年～2024年、2024年～2029年、2034年
• シメチジン
• ラニチジン
• ファモチジン
• ニザチジン
• 世界のH2受容体拮抗薬市場：適応症別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 胃食道逆流症（GERD）
• 消化性潰瘍
• ゾリンジャー・エリソン症候群
• その他の適応症
• 世界のH2受容体拮抗薬市場：投与経路別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 経口
• 静脈内
• 筋肉内
• 世界のH2受容体拮抗薬市場：流通チャネル別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院薬局
• 小売薬局
• オンライン薬局
• その他の流通チャネル
• 世界のH2受容体拮抗薬市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• クリニック
• 在宅ケア設定

第7章 地域別・国別分析

• 世界のH2受容体拮抗薬市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界のH2受容体拮抗薬市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• H2受容体拮抗薬市場：競合情勢
• H2受容体拮抗薬市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Viatris Inc.
• Teva Pharmaceutical Industries Limited
• Boehringer Ingelheim International GmbH
• Sun Pharmaceutical Industries Limited
• Apotex Inc.
• Aurobindo Pharma Limited
• Dr. Reddy's Laboratories Limited
• Cipla Limited
• Hikma Pharmaceuticals plc
• Lupin Ltd.
• Zydus Lifesciences Limited
• Torrent Pharmaceuticals Limited
• Accord Healthcare Limited

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• H2受容体拮抗薬市場2029年：新たな機会を提供する国
• H2受容体拮抗薬市場2029年：新たな機会を提供するセグメント
• H2受容体拮抗薬市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

H2 receptor antagonists are a class of medications that block histamine receptors in the stomach, reducing acid production to treat conditions such as acid reflux, ulcers, and gastroesophageal reflux disease (GERD). These drugs work by inhibiting the H2 receptors on parietal cells in the stomach lining, which are responsible for secreting gastric acid.

The main drug classes of H2 receptor antagonists include cimetidine, ranitidine, famotidine, and nizatidine. Cimetidine is an H2 receptor antagonist that reduces stomach acid production by blocking histamine H2 receptors on the gastric parietal cells. These drugs are indicated for conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, Zollinger-Ellison syndrome, and others. They are administered through various routes, including oral, intravenous, and intramuscular. Distribution channels include hospital pharmacies, retail pharmacies, online pharmacies, and others. The primary end users include hospitals, clinics, and home care settings.

The H2 receptor antagonist market research report is one of a series of new reports from The Business Research Company that provides H2 receptor antagonist market statistics, including the H2 receptor antagonist industry global market size, regional shares, competitors with the H2 receptor antagonist market share, detailed H2 receptor antagonist market segments, market trends, and opportunities, and any further data you may need to thrive in the H2 receptor antagonist industry. This H2 receptor antagonist market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The H2 receptor antagonist market size has grown strongly in recent years. It will grow from $4.08 billion in 2024 to $4.32 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth during the historic period can be attributed to the rising prevalence of peptic ulcers, widespread use of over-the-counter antacids, increasing diagnoses of gastroesophageal reflux disease (GERD), strong adoption in hospital settings, and a rising incidence of gastrointestinal disorders.

The H2 receptor antagonist market size is expected to see strong growth in the next few years. It will grow to $5.35 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The projected growth in the forecast period is driven by rising cases of lifestyle-related digestive disorders, increasing demand for non-prescription gastrointestinal treatments, a growing geriatric population with chronic acid issues, expanding availability of generic formulations, and the development of pediatric-friendly formulations. Key trends expected in the forecast period include the development of extended-release formulations, integration with digital health monitoring tools, innovation in pediatric dosage forms, combination therapies with probiotics, and advances in compound stability for hot climates.

The increasing incidence of gastrointestinal diseases is expected to drive the growth of the H2 receptor antagonist market. Gastrointestinal diseases are conditions that affect the digestive tract, including infections, inflammation, and disorders of the stomach and intestines. The rise in gastrointestinal diseases is largely attributed to unhealthy dietary habits and the increasing consumption of processed foods, which can disrupt gut health and lead to digestive disorders such as acid reflux, irritable bowel syndrome (IBS), and ulcers. H2 receptor antagonists address these conditions by blocking histamine receptors in the stomach, reducing acid production, and alleviating symptoms such as acid reflux, ulcers, and gastritis. For example, in January 2023, the American Cancer Society (ACS) reported a 3.18% increase in gastrointestinal cancer cases in the United States, rising from 338,090 in 2022 to 348,840 in 2023. As a result, the growing incidence of gastrointestinal diseases is driving the expansion of the H2 receptor antagonist market.

Companies in the H2 receptor antagonist market are focusing on developing innovative solutions, such as novel drug delivery systems, to improve the efficacy, convenience, and patient compliance of acid-suppressing treatments. Novel drug delivery systems are advanced technologies designed to release therapeutic agents in a controlled, targeted, and sustained manner for enhanced efficacy and better patient adherence. For instance, in June 2022, Zydus Lifesciences Limited, an India-based pharmaceutical company, launched Famotidine ODT, an orally disintegrating tablet for treating acid-related disorders such as GERD. This formulation allows patients, especially those with difficulty swallowing, to take the medication without water, improving convenience and compliance. Zydus highlighted that this innovation supports better treatment outcomes by making the medication easier to use and providing faster relief. The adoption of such delivery systems is helping to drive growth in the H2 receptor antagonist market by enhancing the therapeutic experience and accessibility for patients.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. This acquisition aims to strengthen Amgen's position in rare diseases and immunology by expanding its portfolio with Horizon's innovative therapies and global commercial capabilities. Horizon Therapeutics, an Ireland-based company, manufactures H2 receptor antagonists, enhancing Amgen's footprint in the gastrointestinal and inflammation treatment market.

Major players in the h2 receptor antagonist market are Pfizer Inc., Sanofi S.A., Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Apotex Inc., Aurobindo Pharma Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals plc, Lupin Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Accord Healthcare Limited.

North America was the largest region in the H2 receptor antagonist market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in H2 receptor antagonist report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the H2 receptor antagonist market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The H2 receptor antagonist market consists of sales of tegoprazan and lansoprazole. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

H2 Receptor Antagonist Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on h2 receptor antagonist market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for h2 receptor antagonist ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The h2 receptor antagonist market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Cimetidine; Ranitidine; Famotidine; Nizatidine
• 2) By Route of Administration: Oral; Intravenous; Intramuscular
• 3) By Indication: Gastroesophageal Reflux Disease (GERD); Peptic Ulcers; Zollinger-Ellison Syndrome; Other Indications
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Other Distribution Channels
• 5) By End-User: Hospitals; Clinics; Home Care Settings
• Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Abbott Laboratories; Novartis AG; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. H2 Receptor Antagonist Market Characteristics

3. H2 Receptor Antagonist Market Trends And Strategies

4. H2 Receptor Antagonist Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global H2 Receptor Antagonist Growth Analysis And Strategic Analysis Framework

• 5.1. Global H2 Receptor Antagonist PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global H2 Receptor Antagonist Market Growth Rate Analysis
• 5.4. Global H2 Receptor Antagonist Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global H2 Receptor Antagonist Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global H2 Receptor Antagonist Total Addressable Market (TAM)

6. H2 Receptor Antagonist Market Segmentation

• 6.1. Global H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cimetidine
• Ranitidine
• Famotidine
• Nizatidine
• 6.2. Global H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Gastroesophageal Reflux Disease (GERD)
• Peptic Ulcers
• Zollinger-Ellison Syndrome
• Other Indications
• 6.3. Global H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Intravenous
• Intramuscular
• 6.4. Global H2 Receptor Antagonist Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
• 6.5. Global H2 Receptor Antagonist Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Clinics
• Home Care Settings

7. H2 Receptor Antagonist Market Regional And Country Analysis

• 7.1. Global H2 Receptor Antagonist Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global H2 Receptor Antagonist Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific H2 Receptor Antagonist Market

• 8.1. Asia-Pacific H2 Receptor Antagonist Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China H2 Receptor Antagonist Market

• 9.1. China H2 Receptor Antagonist Market Overview
• 9.2. China H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India H2 Receptor Antagonist Market

• 10.1. India H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan H2 Receptor Antagonist Market

• 11.1. Japan H2 Receptor Antagonist Market Overview
• 11.2. Japan H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia H2 Receptor Antagonist Market

• 12.1. Australia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia H2 Receptor Antagonist Market

• 13.1. Indonesia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea H2 Receptor Antagonist Market

• 14.1. South Korea H2 Receptor Antagonist Market Overview
• 14.2. South Korea H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe H2 Receptor Antagonist Market

• 15.1. Western Europe H2 Receptor Antagonist Market Overview
• 15.2. Western Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK H2 Receptor Antagonist Market

• 16.1. UK H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany H2 Receptor Antagonist Market

• 17.1. Germany H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France H2 Receptor Antagonist Market

• 18.1. France H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy H2 Receptor Antagonist Market

• 19.1. Italy H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain H2 Receptor Antagonist Market

• 20.1. Spain H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe H2 Receptor Antagonist Market

• 21.1. Eastern Europe H2 Receptor Antagonist Market Overview
• 21.2. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia H2 Receptor Antagonist Market

• 22.1. Russia H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America H2 Receptor Antagonist Market

• 23.1. North America H2 Receptor Antagonist Market Overview
• 23.2. North America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA H2 Receptor Antagonist Market

• 24.1. USA H2 Receptor Antagonist Market Overview
• 24.2. USA H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada H2 Receptor Antagonist Market

• 25.1. Canada H2 Receptor Antagonist Market Overview
• 25.2. Canada H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America H2 Receptor Antagonist Market

• 26.1. South America H2 Receptor Antagonist Market Overview
• 26.2. South America H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil H2 Receptor Antagonist Market

• 27.1. Brazil H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East H2 Receptor Antagonist Market

• 28.1. Middle East H2 Receptor Antagonist Market Overview
• 28.2. Middle East H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa H2 Receptor Antagonist Market

• 29.1. Africa H2 Receptor Antagonist Market Overview
• 29.2. Africa H2 Receptor Antagonist Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa H2 Receptor Antagonist Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa H2 Receptor Antagonist Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. H2 Receptor Antagonist Market Competitive Landscape And Company Profiles

• 30.1. H2 Receptor Antagonist Market Competitive Landscape
• 30.2. H2 Receptor Antagonist Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis

31. H2 Receptor Antagonist Market Other Major And Innovative Companies

• 31.1. Takeda Pharmaceutical Company Limited
• 31.2. Eli Lilly and Company
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceutical Industries Limited
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Sun Pharmaceutical Industries Limited
• 31.7. Apotex Inc.
• 31.8. Aurobindo Pharma Limited
• 31.9. Dr. Reddy's Laboratories Limited
• 31.10. Cipla Limited
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Lupin Ltd.
• 31.13. Zydus Lifesciences Limited
• 31.14. Torrent Pharmaceuticals Limited
• 31.15. Accord Healthcare Limited

32. Global H2 Receptor Antagonist Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The H2 Receptor Antagonist Market

34. Recent Developments In The H2 Receptor Antagonist Market

35. H2 Receptor Antagonist Market High Potential Countries, Segments and Strategies

• 35.1 H2 Receptor Antagonist Market In 2029 - Countries Offering Most New Opportunities
• 35.2 H2 Receptor Antagonist Market In 2029 - Segments Offering Most New Opportunities
• 35.3 H2 Receptor Antagonist Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer